News

Filter

Current filters:

vemurafenib

Chugai files NDA for vemurafenib for melanoma

Chugai files NDA for vemurafenib for melanoma

11-04-2014

Japanese drugmaker Chugai Pharmaceutical has filed a new drug application to the Ministry of Health,…

BRAFV600ChemistryChugai PharmaceuticalJapanJO28178OncologyOrganochloridesPharmaceuticalRegulationRoche Diagnosticsvemurafenib

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

Roche’s Zelboraf and companion diagnostic for late-stage melanoma cleared in USA

18-08-2011

Swiss drug major Roche (ROG: SIX) yesterday received US Food and Drug Administration approval for Zelboraf…

North AmericaOncologyPharmaceuticalRegulationRochevemurafenibZelboraf

Chugai gets rights to Roche melanoma drug vemurafenib in Japan

15-08-2011

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said yesterday that it has entered into a license…

Chugai PharmaceuticalLicensingOncologyPharmaceuticalRochevemurafenib

Unprecedented survival results for B-MS Yervoy and Roche’s vemurafenib in melanoma discussed at ASCO

07-06-2011

There was exciting news presented at this year’s American Society of Clinical Oncology meeting for…

Bristol-Myers SquibbDaiichi SankyoOncologyPharmaceuticalPlexxikonResearchRochevemurafenibYervoy

Bristol-Myers Squibb and Roche link to test Yervoy and vemurafenib for melanoma

03-06-2011

US drug major Bristol-Myers Squibb (NYSE: BMY) has joined forces with Swiss major Roche (SIX: ROG) to…

Bristol-Myers SquibbOncologyPharmaceuticalResearchRochevemurafenibYervoy

Roche files for US and EU approval of vemurafenib for metastatic skin cancer

12-05-2011

US biotech giant Genentech, part of Swiss drug major Roche (SIX: ROG), has submitted a New Drug Application…

Bristol-Myers SquibbDaiichi SankyoEuropeGenentechNorth AmericaOncologyPharmaceuticalPlexxikonRegulationRochevemurafenibYervoy

COMPANY SPOTLIGHT

Menarini

Back to top